MOLECULES WHICH BIND TO PSL PSEUDOMONAS, AND METHODS FOR USE THEREOF Russian patent published in 2019 - IPC C07K16/12 

FIELD: pharmaceuticals.

SUBSTANCE: invention refers to an isolated antibody or its antigen-binding fragment which specifically binds Psl Pseudomonas, and a pharmaceutical composition containing said antibody. Antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), which contain amino acid sequences VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, selected from a group consisting of: SEQ ID NO: 17, 18, 19, 20, 21 and 22 (Cam-003), SEQ ID NO: 23, 24, 25, 20, 21 and 22 (Cam-004), SEQ ID NO: 26, 27, 28, 20, 21 and 22 (Cam-005), SEQ ID NO: 29, 30, 31, 32, 33 and 34 (WapR-001), SEQ ID NO: 35, 36, 37, 38, 39 and 40 (WapR-002), SEQ ID NO: 41, 42, 43, 44, 45 and 46 (WapR-003), SEQ ID NO: 47, 48, 49, 50, 51 and 52 (WapR-004), SEQ ID NO: 47, 48, 75, 50, 51 and 52 (WapR-004RAD) and SEQ ID NO: 59, 60, 61, 62, 63 and 64 (WapR-016). Antibody promotes opsonophagocytic destruction (OPK) of P. aeruginosa and, optionally, can inhibit attachment of P. aeruginosa to epithelial cells. Pharmaceutical composition for preventing or treating Pseudomonas infection contains an effective amount of said antibody or fragment thereof and a carrier.

EFFECT: inventions can be used for effective prevention or treatment of Pseudomonas infection.

12 cl, 21 dwg, 4 tbl, 13 ex